Pure Bioscience annual revenue
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Pure Bioscience Revenue Growth & History (PURE)
Pure Bioscience reported $2.2M in revenue for fiscal 2025, an increase of 12.18% from the previous fiscal year.
View full Pure Bioscience company overviewPure Bioscience annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-07-31 | $2.2M | $239,000 | +12.18% |
| 2024 | 2024-07-31 | $2.0M | $86,000 | +4.58% |
| 2023 | 2023-07-31 | $1.9M | $24,000 | +1.30% |
| 2022 | 2022-07-31 | $1.9M | −$2.1M | −52.81% |
| 2021 | 2021-07-31 | $3.9M | −$3.0M | −43.23% |
| 2020 | 2020-07-31 | $6.9M | $5.0M | +262.34% |
| 2019 | 2019-07-31 | $1.9M | $135,000 | +7.61% |
| 2018 | 2018-07-31 | $1.8M | −$57,000 | −3.11% |
| 2017 | 2017-07-31 | $1.8M | $542,000 | +42.05% |
| 2016 | 2016-07-31 | $1.3M | $560,000 | +76.82% |
| 2015 | 2015-07-31 | $729,000 | $179,000 | +32.55% |
| 2014 | 2014-07-31 | $550,000 | −$270,000 | −32.93% |
| 2013 | 2013-07-31 | $820,000 | $8,000 | +0.99% |
| 2012 | 2012-08-14 | $812,000 | $348,000 | +75.00% |
| 2011 | 2011-07-31 | $464,000 | — | — |
Pure Bioscience quarterly revenue
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
Q3.26
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q3 2026 | 2026-04-30 | $506,000 | $15,000 | +3.05% |
| Q2 2026 | 2026-01-31 | $444,000 | $53,000 | +13.55% |
| Q1 2026 | 2025-10-31 | $708,000 | $152,000 | +27.34% |
| Q4 2025 | 2025-07-31 | $764,000 | $290,000 | +61.18% |
| Q3 2025 | 2025-04-30 | $491,000 | $50,000 | +11.34% |
| Q2 2025 | 2025-01-31 | $391,000 | $65,000 | +19.94% |
| Q1 2025 | 2024-10-31 | $556,000 | −$166,000 | −22.99% |
| Q4 2024 | 2024-07-31 | $474,000 | −$128,000 | −21.26% |
| Q3 2024 | 2024-04-30 | $441,000 | $34,000 | +8.35% |
| Q2 2024 | 2024-01-31 | $326,000 | −$71,000 | −17.88% |
| Q1 2024 | 2023-10-31 | $722,000 | $251,000 | +53.29% |
| Q4 2023 | 2023-07-31 | $602,000 | $190,000 | +46.12% |
| Q3 2023 | 2023-04-30 | $407,000 | −$117,000 | −22.33% |
| Q2 2023 | 2023-01-31 | $397,000 | −$19,000 | −4.57% |
| Q1 2023 | 2022-10-31 | $471,000 | −$30,000 | −5.99% |
| Q4 2022 | 2022-07-31 | $412,000 | −$447,000 | −52.04% |
| Q3 2022 | 2022-04-30 | $524,000 | −$37,000 | −6.60% |
| Q2 2022 | 2022-01-31 | $416,000 | −$500,000 | −54.59% |
| Q1 2022 | 2021-10-31 | $501,000 | −$1.1M | −68.51% |
| Q4 2021 | 2021-07-31 | $859,000 | −$3.1M | −78.25% |
| Q3 2021 | 2021-04-30 | $561,000 | −$1.7M | −74.74% |
| Q2 2021 | 2021-01-31 | $916,000 | $567,000 | +162.46% |
| Q1 2021 | 2020-10-31 | $1.6M | $1.2M | +299.75% |
| Q4 2020 | 2020-07-31 | $3.9M | $3.3M | +544.21% |
| Q3 2020 | 2020-04-30 | $2.2M | $1.9M | +611.86% |
| Q2 2020 | 2020-01-31 | $349,000 | −$45,000 | −11.42% |
| Q1 2020 | 2019-10-31 | $398,000 | −$192,000 | −32.54% |
| Q4 2019 | 2019-07-31 | $613,000 | $104,000 | +20.43% |
| Q3 2019 | 2019-04-30 | $312,000 | −$78,000 | −20.00% |
| Q2 2019 | 2019-01-31 | $394,000 | −$17,000 | −4.14% |
| Q1 2019 | 2018-10-31 | $590,000 | $126,000 | +27.16% |
| Q4 2018 | 2018-07-31 | $509,000 | −$6,000 | −1.17% |
| Q3 2018 | 2018-04-30 | $390,000 | $52,000 | +15.38% |
| Q2 2018 | 2018-01-31 | $411,000 | −$36,000 | −8.05% |
| Q1 2018 | 2017-10-31 | $464,000 | −$67,000 | −12.62% |
| Q4 2017 | 2017-07-31 | $515,000 | −$9,000 | −1.72% |
| Q3 2017 | 2017-04-30 | $338,000 | −$65,000 | −16.13% |
| Q2 2017 | 2017-01-31 | $447,000 | $271,000 | +153.98% |
| Q1 2017 | 2016-10-31 | $531,000 | $345,000 | +185.48% |
| Q4 2016 | 2016-07-31 | $524,000 | $294,000 | +127.83% |
| Q3 2016 | 2016-04-30 | $403,000 | $294,000 | +269.72% |
| Q2 2016 | 2016-01-31 | $176,000 | −$97,000 | −35.53% |
| Q1 2016 | 2015-10-31 | $186,000 | $69,000 | +58.97% |
| Q4 2015 | 2015-07-31 | $230,000 | $97,000 | +72.93% |
| Q3 2015 | 2015-04-30 | $109,000 | −$152,000 | −58.24% |
| Q2 2015 | 2015-01-31 | $273,000 | $232,000 | +565.85% |
| Q1 2015 | 2014-10-31 | $117,000 | $2,000 | +1.74% |
| Q4 2014 | 2014-07-31 | $133,000 | −$56,000 | −29.63% |
| Q3 2014 | 2014-04-30 | $261,000 | $3,000 | +1.16% |
| Q2 2014 | 2014-01-31 | $41,000 | −$222,000 | −84.41% |
| Q1 2014 | 2013-10-31 | $115,000 | $5,000 | +4.55% |
| Q4 2013 | 2013-07-31 | $189,000 | $62,000 | +48.82% |
| Q3 2013 | 2013-04-30 | $258,000 | $51,000 | +24.64% |
| Q2 2013 | 2013-01-31 | $263,000 | $42,000 | +19.00% |
| Q1 2013 | 2012-10-31 | $110,000 | −$147,000 | −57.20% |
| Q4 2012 | 2012-08-14 | $127,000 | −$118,000 | −48.16% |
| Q3 2012 | 2012-04-30 | $207,000 | $79,000 | +61.72% |
| Q2 2012 | 2012-01-31 | $221,000 | $153,000 | +225.00% |
| Q1 2012 | 2011-10-31 | $257,000 | $234,000 | +1017.39% |
| Q4 2011 | 2011-07-31 | $245,000 | — | — |
| Q3 2011 | 2011-04-30 | $128,000 | — | — |
| Q2 2011 | 2011-01-31 | $68,000 | — | — |
| Q1 2011 | 2010-10-31 | $23,000 | — | — |
Pure Bioscience revenue growth trends
Over the last five reported fiscal years, revenue declined from $6.9M to $2.2M, a compound annual decline of 20.46%. Pure Bioscience's latest reported quarter, Q3 2026, generated $506,000 in revenue, an increase of 3.05% year over year.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review Pure Bioscience source filings ↗